Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
OBJECTIVE
Determine the prevalence of metabolic abnormalities (MA) and estimate the 10-year risk for cardiovascular disease (CVD) among Latin American HIV-infected patients receiving highly active anti-retroviral therapy (HAART).


METHODS
A cohort study to evaluate MA and treatment practices to reduce CVD has been conducted in seven Latin American countries. Adult HIV-infected patients with at least one month of HAART were enrolled. Baseline data are presented in this analysis.


RESULTS
A total of 4,010 patients were enrolled. Mean age (SD) was 41.9 (10) years; median duration of HAART was 35 (IQR: 10-51) months, 44% received protease inhibitors. The prevalence of dyslipidemia and metabolic syndrome was 80.2% and 20.2%, respectively. The overall 10-year risk of CVD, as measured by the Framingham risk score (FRF), was 10.4 (24.7). Longer exposure to HAART was documented in patients with dyslipidemia, metabolic syndrome and type 2 diabetes mellitus. The FRF score increased with duration of HAART. Male patients had more dyslipidemia, high blood pressure, smoking habit and higher 10-year CVD than females.


CONCLUSIONS
Traditional risk factors for CVD are prevalent in this setting leading to intermediate 10-year risk of CVD. Modification of these risk factors through education and intervention programs are needed to reduce CVD.
Cahn
P
P
Huésped Foundation, Buenos Aires, Argentina.
Leite
O
O
Rosales
A
A
Cabello
R
R
Alvarez
C A
CA
Seas
C
C
Carcamo
C
C
Cure-Bolt
N
N
L'Italien
G P
GP
Mantilla
P
P
Deibis
L
L
Zala
C
C
Suffert
T
T
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D050171:Dyslipidemias / Q000139:chemically induced; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007843:Latin America; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced*; D024821:Metabolic Syndrome / Q000139:chemically induced; D008875:Middle Aged; D012307:Risk Factors
D019380:Anti-HIV Agents